NeuroProtect
Novel Drug Therapy with Potential to Cure Neuro-Degenerative Diseases
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0NeuroProtect project word cloud
Explore the words cloud of the NeuroProtect project. It provides you a very rough idea of what is the project "NeuroProtect" about.
Project "NeuroProtect" data sheet
The following table provides information about the project.
| Coordinator |
SUNREGEN HEALTHCARE AG
Organization address contact info |
| Coordinator Country | Switzerland [CH] |
| Project website | http://www.sunregen.ch |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-06-01 to 2018-09-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | SUNREGEN HEALTHCARE AG | CH (Reinach) | coordinator | 50˙000.00 |
Map
Project objective
Over 10M Europeans suffer from neurodegenerative diseases such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Whilst there are many drugs that treat symptoms of these diseases, there are no therapies that can reverse or cure them. Our novel compound NeuroProtect has the potential to be a game changer by healing damaged neurons. NeuroProtect is a natural herb-derived compound with remarkable neuroprotective, neuro-rescuing, anti-apoptotic, and axon-outgrowth effects in mouse primary neuronal and human neuronal models. We have proven the compound’s efficiency in preliminary in-vitro tests. To take NeuroProtect to market fastest, we will focus on ALS that where we can use the orphan drug route and get clinical approval faster. This gives us an immediate target market of €300M per year in Europe, the US, Japan and Switzerland alone. Although ALS is relatively rare, the socioeconomic significance of the disease is extensive: a recent study showed that total lifetime costs for ALS were €1.15M per patient. NeuroProtect can therefore contribute to reduce the global economic burden of ALS. We are planning to take the standard route for commercialization in pharma industry: take the compound through pre-clinical studies, Phase I and Phase II clinical trials and then outlicense to a large pharma company who will refund our cost until they finish the Phase III trials and then pay us royalties. Our team is led by two experienced co-founders: Dr. Yuhong Dong, who has worked for a multinational pharmaceutical company for over 10 years as well as a physician for 4 years, and David Guan, who has over 10 years of management positions at multinational companies (HP, Honeywell). We are also supported by experienced advisors and investors to help us succeed. We are planning to use the Phase 1 funding to select our pre-clinical study partners, perform a market assessment, assess our IP strategy and update our business plan.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUROPROTECT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEUROPROTECT" are provided by the European Opendata Portal: CORDIS opendata.